Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Aclidinium bromide and formoterol fumarate

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Aclidinium bromide and formoterol fumarate key facts

Used for
DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (August 1, 2022); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Aclidinium bromide and formoterol fumarate used for?
The FDA-approved label (Duaklir Pressair, Covis Pharma US, Inc, August 1, 2022) says: “DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Aclidinium bromide and formoterol fumarate?
The “Adverse Reactions” section of the FDA label (Duaklir Pressair, Covis Pharma US, Inc, August 1, 2022) begins: “LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. DUAKLIR PRESSAIR is not indicated for the treatment of asthma [see Warnings and Precautions (5.1)].” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Aclidinium bromide and formoterol fumarate?
The “Drug Interactions” section of the FDA label (Duaklir Pressair, Covis Pharma US, Inc, August 1, 2022) begins: “No formal drug interaction studies have been performed with DUAKLIR PRESSAIR. • Use of other adrenergic by any route may potentiate the effect of DUAKLIR PRESSAIR. Use with caution. (5.3, 7.1) • Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. (7.2, 7.3) • Diuretics: Use with caution.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Aclidinium bromide and formoterol fumarate have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Aclidinium bromide and formoterol fumarate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Aclidinium bromide and formoterol fumarate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Aclidinium bromide and formoterol fumarate?
1 company lists prescription products of Aclidinium bromide and formoterol fumarate in the FDA NDC Directory, including Covis Pharma US, Inc.

What Aclidinium bromide and formoterol fumarate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma […]. …

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. Read the full label on DailyMed →

Label quoted: the one for the most common form (powder, metered, respiratory (inhalation)), Duaklir Pressair, Covis Pharma US, Inc; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Aclidinium bromide and formoterol fumarate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. DUAKLIR PRESSAIR is not indicated for the treatment of asthma [see Warnings and Precautions (5.1)].

Read more of this section

The following adverse reactions are described in greater detail elsewhere in the labeling:

  • Paradoxical bronchospasm [see Warnings and Precautions (5.4)]
  • Immediate hypersensitivity reactions [see Contraindications (4), Warnings and Precautions (5.5)]
  • Cardiovascular effects [see Warnings and Precautions (5.6)]
  • Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.9)]
  • Worsening of urinary retention [see Warnings and Precautions (5.10)] Most common adverse reactions (incidence ≥ 3% and more common than with placebo) include: upper respiratory tract infection, headache and, back pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 1-877-411-2510 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The clinical program for DUAKLIR PRESSAIR included 6501 subjects with COPD in 2 placebo-controlled and 1 active-controlled 24-week lung function trials, one long-term safety extension study of 28 weeks and 2 other clinical trials. A total of 1893 subjects have received at least 1 dose of DUAKLIR PRESSAIR. 24-Week Trials The frequency of common adverse reactions in Table 1 below is based upon pooled data from two, double-blind, placebo-controlled parallel group clinical trials (Trials 1 and 2, n=1729 and n=1669) in 3398 adult patients with moderate to severe COPD. Of these, 60% were male and 94% were Caucasian. They had a mean age of 64 years and an average smoking history of 46 pack-years, with 49% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV 1) was 54% (range: 28% to 80%) and the mean percent reversibility was 15% (range: -19% to 69%). Table 1 shows all adverse reactions that occurred with a frequency of greater than or equal to 3% in the DUAKLIR PRESSAIR group in the two 24-week placebo-controlled trials where the rates in the DUAKLIR PRESSAIR group exceeded placebo.
Table from the label
Treatment
Adverse ReactionsPreferred TermDUAKLIR PRESSAIR(N=720)%Aclidinium(N=722)%Formoterol(N=716)%Placebo(N=526)%
Upper respiratory tract infectionIncludes Viral Upper Respiratory Tract Infection and Upper Respiratory Tract Infection8.97.68.96.3
Headache6.36.67.75.1
Back pain3.83.33.53.4

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. This is part of the section. Read the full label on DailyMed →

Aclidinium bromide and formoterol fumarate drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

No formal drug interaction studies have been performed with DUAKLIR PRESSAIR.

  • Use of other adrenergic by any route may potentiate the effect of DUAKLIR PRESSAIR. Use with caution. (5.3, 7.1)
  • Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. (7.2, 7.3)
  • Diuretics: Use with caution.
Read more of this section

Electrocardiographic changes and/or hypokalemia associated with non-potassium sparing diuretics may worsen with concomitant beta 2 -agonists. (7.3)

  • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol fumarate on cardiovascular system. (7.4)
  • Beta-blockers: Use with caution and only when medically necessary. (7.5)
  • Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administrations of DUAKLIR PRESSAIR with other anticholinergic-containing drugs. (7.6) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol, a component of DUAKLIR PRESSAIR, may be potentiated [see Warnings and Precautions (5.7)]. 7.2 Xanthine Derivatives, Steroids Concomitant treatment with xanthine derivatives, or steroids may potentiate any hypokalemic effect of beta-adrenergic agonists such as formoterol, a component of DUAKLIR PRESSAIR. 7.3 Non-Potassium Sparing Diuretics The electrocardiographic changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non–potassium-sparing diuretics. 7.4 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants, QTc Prolonging Drugs DUAKLIR PRESSAIR, as with other drugs containing beta 2 -agonists, should be administered with caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs known to prolong the QTc interval, because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias. 7.5 Beta-Blockers Beta-adrenergic receptor antagonists (beta-blockers) and DUAKLIR PRESSAIR may inhibit the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta 2 -agonists, such as formoterol, a component of DUAKLIR PRESSAIR, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD.

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. This is part of the section. Read the full label on DailyMed →

Aclidinium bromide and formoterol fumarate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

The recommended dose of DUAKLIR PRESSAIR is one oral inhalation of 400 mcg/12 mcg, twice daily (once in the morning and once in the evening). Do not take more than one inhalation twice daily.

  • For oral inhalation only. (2)
  • 400 mcg/12 mcg, twice daily (once in the morning and once in the evening). (2)

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. Read the full label on DailyMed →

Aclidinium bromide and formoterol fumarate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary There are no adequate and well-controlled studies of DUAKLIR PRESSAIR or its individual components, formoterol fumarate or aclidinium bromide, in pregnant women to inform drug-associated risks. No adverse developmental effects were seen with inhalation administration of aclidinium bromide to pregnant rats and rabbits during organogenesis at 15 or 20 times, respectively, the maximum recommended human daily inhaled dose (MRHDID).

Read more of this section

However, reduced pup weights were seen when pregnant rats continued inhalation administration through lactation at 5 times the MRHDID of aclidinium bromide. Adverse developmental effects occurred when rabbits were orally dosed with aclidinium bromide at approximately 1,400 times the MRHDID [see Data]. Formoterol fumarate alone, administered by the oral route, was teratogenic in rats and rabbits at 1,200 and 49,000 times the MRHDID, respectively. Formoterol fumarate was also embryocidal, increased pup loss at birth and during lactation, and decreased pup weight in rats at 85 times the MRHDID. These adverse effects generally occurred at large multiples of the MRHDID when formoterol fumarate was administered by the oral route to achieve high systemic exposures. No teratogenic, embryocidal, or developmental effects were seen in rats that received inhalation doses up to 280 times the MRHDID [see Data]. The estimated background risk of major birth defects and miscarriage of the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Labor or Delivery There are no well-controlled human studies that have investigated the effects of DUAKLIR PRESSAIR during labor and delivery. Because of the potential for beta-agonist interference with uterine contractility, use of DUAKLIR PRESSAIR during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Data Animal Data Aclidinium bromide In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6-17, no evidence of structural alterations was observed at approximately 15 times the maximum recommended human daily inhaled dose (MRHDID) [based on summed AUCs of aclidinium bromide and its metabolites at inhaled doses less than or equal to 5.0 mg/kg/day]. However, in a pre- and post-natal development study, decreased pup weights were observed when pregnant rats were exposed from gestation day 6 and continuing during the lactation period at approximately 5 times the MRHDID [based on summed AUCs of aclidinium bromide and its metabolites at inhaled doses greater than or equal to 0.2 mg/kg/day]. Maternal toxicity was also observed at inhaled doses greater than or equal to 0.2 mg/kg/day.

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. This is part of the section. Read the full label on DailyMed →

When Aclidinium bromide and formoterol fumarate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Use of a long-acting beta 2 -adrenergic agonist (LABA), including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1)]. DUAKLIR PRESSAIR is not indicated for the treatment of asthma. DUAKLIR PRESSAIR is contraindicated in patients with:

  • Severe hypersensitivity to milk proteins [see Warnings and Precautions (5.5)].
Read more of this section
  • Hypersensitivity to aclidinium bromide, formoterol fumarate, or to any component of the product [see Warnings and Precautions (5.5)].
  • Use of a long-acting beta 2 -adrenergic agonist (LABA), including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid is contraindicated in patients with asthma. (1, 4)
  • Hypersensitivity to aclidinium bromide or formoterol fumarate or to any component of this product. (4, 5.5)

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. Read the full label on DailyMed →

Aclidinium bromide and formoterol fumarate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

DUAKLIR PRESSAIR contains both aclidinium and formoterol fumarate; therefore, the risks associated with overdosage for the individual components described below apply to DUAKLIR PRESSAIR. The most common symptoms are blurred vision, dry mouth, nausea, muscle spasms, tremor, headache, palpitations, and systolic hypertension. Treatment of overdosage consists of discontinuation of DUAKLIR PRESSAIR together with institution of appropriate symptomatic and/or supportive therapy.

— FDA label: Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022. Read the full label on DailyMed →

Forms and how it is given

Dosage formsPowder, metered
RouteRespiratory (inhalation)
Prescription products1 in the FDA NDC Directory
Brand namesDuaklir Pressair

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA210595
DUAKLIR PRESSAIR
AzurityMarch 29, 2019 —

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2205094, 2205099, 2205103, 2205104
SPL set ID of the quoted label2eba3089-28b4-4190-9fba-2511246cfd16
FDA labels (SPL)1
FDA applicationsNDA210595
Active ingredients (FDA)ACLIDINIUM / FORMOTEROL

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Duaklir Pressair, Covis Pharma US, Inc, effective August 1, 2022; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers